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diet: a randomised controlled trial in healthy 
obese women
Julia Otten1, Mats Ryberg1, Caroline Mellberg1, Tomas Andersson1, Elin Chorell1, 
Bernt Lindahl1, Christel Larsson2, Jens Juul Holst3 and Tommy Olsson1
1Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden, 2Department of Food and 
Nutrition, and Sport Science, University of Gothenburg, Gothenburg, Sweden, and 3NNF Center for Basal Metabolic 
Research and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
Abstract
Objective: To investigate how weight loss by different diets impacts postprandial levels of glucagon-like peptide 1  
(GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon.
Methods: In this single-centre, parallel group 2-year trial, 70 healthy postmenopausal obese women were randomised 
to the Paleolithic diet or a healthy control diet based on Nordic Nutrition Recommendations. Both diets were without 
calorie restriction. The primary outcome was the change in fat mass. Here, secondary analyses on GLP-1, GIP and 
glucagon measured during an OGTT are described.
Results: In the Paleolithic diet group, mean weight loss compared to baseline was 11% at 6 months and 10% at 
24 months. In the control diet group, mean weight loss was 6% after 6 and 24 months (P = 0.0001 and P = 0.049 for 
the comparison between groups at 6 and 24 months respectively). Compared to baseline, the mean incremental area 
under the curve (iAUC) for GLP-1 increased by 34 and 45% after 6 and 24 months in the Paleolithic diet group and 
increased by 59% after 24 months in the control diet group. The mean iAUC for GIP increased only in the Paleolithic 
diet group. The area under the curve (AUC) for glucagon increased during the first 6 months in both groups. The 
fasting glucagon increase correlated with the β-hydroxybutyrate increase.
Conclusions: Weight loss caused an increase in postprandial GLP-1 levels and a further rise occurred during weight 
maintenance. Postprandial GIP levels increased only after the Paleolithic diet. Reduced postprandial glucagon 
suppression may be caused by a catabolic state.
Introduction
Obesity is a major cause of cardiovascular disease and 
cancer, and its prevalence is increasing worldwide 
(1). Thus, it is critical to find effective treatments. An 
important issue is the regain of weight after different 
lifestyle interventions. This is at least partly due to 
resumption of previous lifestyle habits but also has 
physiological reasons. Importantly, diet composition 
may be important for weight loss maintenance 
with a high-protein and low-carbohydrate diet 
potentially being associated with improved body 
weight maintenance (2). Diet composition may also 
impact the secretion of hormones involved in the 
homeostatic regulation of body weight loss and weight 
maintenance.
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A Paleolithic diet is based on fruit, vegetables, eggs, 
nuts, fish and lean meat and excludes salt, refined 
sugar, cereals and dairy products. By adhering to these 
recommendations, the Paleolithic diet contains compared 
to other diets less carbohydrate and more protein and 
unsaturated fat (3, 4, 5). A Paleolithic diet has been shown 
to improve glucose tolerance in individuals with ischaemic 
heart disease and HbA1c, triglycerides and blood pressure 
in patients with type 2 diabetes (3, 4, 6).
When nutrients pass through the intestine, 
enteroendocrine cells in the intestinal epithelium secrete 
the incretin hormones glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic polypeptide (GIP) 
into the circulation. Both incretins stimulate insulin 
secretion; GLP-1 also inhibits glucagon secretion and 
enhances satiety (7, 8, 9). Compared to lean individuals, 
overweight individuals show a reduced postprandial GLP-1 
response (10, 11). On the other hand, GIP levels after 
food intake are either increased or similar in overweight 
compared to lean individuals (11, 12). Notably, it is not 
clear if alternations in incretin secretion are clinically 
important for weight loss and weight maintenance. 
Earlier investigations have thus reported both increasing 
and decreasing postprandial GLP-1 and GIP levels after 
diet-induced weight loss (13, 14, 15).
The pancreatic hormone glucagon is also involved 
in appetite regulation and is strongly regulated by plasma 
amino acids, suggesting that glucagon can be involved in 
appetite inhibition after protein-rich diets (16). When plasma 
glucose levels decrease, pancreatic alpha cells respond with 
increased glucagon secretion. In contrast, during glucose 
administration glucagon levels drop. This suppression 
of glucagon secretion is impaired in patients with type 2 
diabetes and possibly also in overweight individuals (17).
Here, we report a 2-year study, in which we found 
excellent weight loss during the first 6  months and 
absence of weight regain during the rest of the study 
period. Our hypothesis was that postprandial incretin 
levels increase and postprandial glucagon levels remain 
unchanged during weight loss. By randomisation, we 
aimed to investigate if diet composition or weight loss per 
se affects postprandial incretin and glucagon levels.
Subjects and methods
Study design
For a 2-year period, overweight postmenopausal women 
were randomised to follow either a Paleolithic diet or 
a healthy control diet based on the Nordic Nutrition 
Recommendations.
Subjects and randomisation
The subjects and the intervention have previously been 
described in detail (18). Briefly, healthy postmenopausal 
women (BMI of 27–41 kg/m2) were recruited using 
advertisements in local newspapers, and posters within 
the Umeå University Hospital area, between September 
2007 and February 2008. The study was finished in 2010. 
Exclusion criteria were diabetes or fasting plasma glucose 
of ≥7 mmol/L; presence of severe disease; and treatment 
with statins, beta-blockers, hormone replacement or any 
medication for psychiatric disorders. A total of 70 women 
were randomised (Fig.  1). All study personnel, except 
the dieticians, were blind to the participants’ dietary 
allocations. The participants provided written informed 
consent, and the study was approved by the Regional 
Ethical Review Board at Umeå University.
Diet intervention
After randomisation, study participants attended group 
sessions led by dieticians and cooking classes. Each 
individual participated in a total of 12 group sessions 
throughout the intervention period. Eight of the group 
sessions (including four cooking classes) took place during 
the first 6 months of the intervention. In both diets, energy 
intake was without calorie restriction. The Paleolithic diet 
was designed to increase protein intake to 30% of total 
energy (E%) and to provide 30 E% from carbohydrates 
and 40 E% from fat. It included fish, seafood, lean meat, 
eggs, nuts, vegetables, fruits, berries and vegetable oils, 
and excluded cereals, dairy products and added sugar and 
salt. The healthy control diet, a prudent diet based on 
the Nordic Nutrition Recommendations, was designed to 
decrease fat intake to 30 E% and to provided 55 E% from 
carbohydrates and 15 E% from protein (19). In this diet 
group, the women were advised to increase their intake of 
fruit, vegetables, whole grain and fish and to eat low-fat 
meat and dairy products.
Measurements
In a fasting state, participants came for assessments at 
the Clinical Research Department, Umeå University 
Hospital. Fat mass was measured by dual-energy X-ray 
absorptiometry (GE Medical Systems). They were 
instructed to drink an oral glucose bolus of 75 g dissolved 
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in water within 5 min. Blood samples were drawn prior 
to glucose ingestion, and every 30 min for a total of 2 h. 
Plasma glucose and insulin were immediately analysed at 
the Department for Clinical Chemistry, Umeå University 
Hospital. For other analyses, plasma samples were stored 
at −80°C and analysed in batch in January 2014.
Glucagon was measured using a radioimmunological 
assay directed against the COOH terminus, as previously 
described (20, 21, 22). Total plasma GLP-1 concentration 
(intact GLP-1 plus the metabolite GLP-1 9-36 amide) was 
also assayed via a previously described radioimmunological 
method (23, 24). The analytical detection limit for both 
glucagon and GLP-1 was 1 pmol/L. Total plasma GIP 
concentration (the sum of intact GIP plus the metabolite 
GIP 3-42) was measured by radioimmunoassay, as 
previously described (24, 25). The AUC was calculated 
using the trapezoidal rule, and both total AUC and 
incremental (baseline subtracted) AUC were determined. 
Glucagon decreases during the OGTT and only the total 
AUC was used.
The plasma concentration of β-hydroxybutyrate was 
measured using gas chromatography coupled to mass 
Figure 1
CONSORT flow diagram.
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spectrometry (GC-MS). Prior to GC-MS analysis, plasma 
samples were extracted with methanol/water (90/10, 
v/v) and spiked with isotope-labelled internal standards, 
followed by a two-step derivatisation procedure (26). The 
derivatised samples (1 μL) were analysed on an Agilent 
6890 gas chromatograph, equipped with a 10 m × 0.18 mm 
i.d. fused silica capillary column with a chemically 
bonded 0.18-µm DB 5-MS stationary phase (J&W 
Scientific, Folsom, CA, USA). The injector temperature 
was 270°C. The column temperature was held at 70°C for 
2 min, increased by 40°C/min to 320°C and held there for 
1 min. The column effluent was introduced into the ion 
source of a Pegasus III time-of-flight mass spectrometer 
(GC-TOF/MS; Leco, St. Joseph, MI, USA). The transfer line 
temperature was 250°C, and the ion source temperature 
was 200°C. Ions were generated by a 70-eV electron beam 
at a 2.0-mA ionisation current. Spectra were recorded in 
the mass range 50–800 m/z, at a rate of 30 spectra/s. The 
unique mass-to-charge (m/z) ratio of 191 was used to 
quantify β-hydroxybutyrate. This method gives no exact 
concentration but relative concentrations that enable 
comparison between groups/timepoints.
The plasma concentration of non-esterified fatty acids 
was analysed using the NEFA-HR2 kit (Wako Chemicals).
Energy and macronutrient intake were assessed by 
4-day self-reported food diaries. For validation of protein 
intake study participants collected three 24-h urine 
samples for analysis of nitrogen excretion at baseline, 
6  months and 24  months as reported earlier (18). 
Analytical precision was ±10%.
Power analysis, randomisation and 
statistical analysis
We performed a secondary analysis of the 2-year diet 
intervention (18). The primary outcome of the study was 
the change in fat mass over a period of 2  years. Power 
calculation based on this objective indicated that 35 
subjects were needed in each intervention arm to achieve 
a significant outcome (P < 0.05) with 80% power. In a 
previous study of 20 obese individuals, weight loss altered 
postprandial GLP-1 and GIP levels (14), indicating that 
we should have enough power for the secondary analysis 
described in this paper, despite the relatively high loss-
to-follow-up rate. Randomisation of this single-centre, 
parallel group trial was performed by a statistician blinded 
to the study, using a block size of four and a 1:1 allocation 
ratio. Baseline values and treatment effects (change from 
baseline to 6  months and from baseline to 24  months) 
were compared between groups using the Mann–Whitney 
U test. Within-group changes over time from baseline to 
6 months and from baseline to 24 months were analysed 
using the Wilcoxon signed-rank test. Correlation analyses 
were performed by calculating Spearman’s rho (rS). A 
two-sided P value of <0.05 was considered statistically 
significant. Statistical analyses were performed using 
SPSS 24.0 for Mac (IBM Corp). Data are presented as 
mean ± s.e.m. unless otherwise stated.
Results
Dietary adherence
A previous publication describes the dietary adherence, 
and effects of each diet on parameters of the metabolic 
syndrome (18). During the intervention both diet groups 
decreased their energy intake (Table 1). According to food 
diaries, the Paleolithic diet group decreased carbohydrate 
intake more than the control diet group (P = 0.0003 and 
P = 0.002 for the comparison between groups at 6 and 
24 months respectively, Table 1). At 6 months, fat intake 
in the control diet group decreased more than that in 
the Paleolithic diet group (P < 0.0001 for the comparison 
between groups, Table 1).
According to measurements of nitrogen excretion, 
both diet groups increased protein intake (E%) during 
the first 6 months of intervention, but after 24 months 
only the Paleolithic diet group had increased protein 
intake (E%) compared to baseline (Table 1). Protein intake 
(E%) reported by the participants in food diaries showed 
comparable results (Table 1). Reported protein intake (E%) 
and measured protein intake by nitrogen excretion (E%) 
were highly correlated (rS = 0.54, P < 0.0001).
Body weight and fat mass
Baseline characteristics did not significantly differ between 
groups (Table 2). Individuals following the Paleolithic diet 
lost significantly more weight than those in the control 
diet group (P = 0.0001 and P = 0.048 for the comparison 
between groups at 6 and 24 months respectively, Table 2). 
In the Paleolithic diet group, the mean weight loss 
compared to baseline was 11% after 6 months and 10% 
after 24  months. In the control diet group, the mean 
weight loss compared to baseline was 6% after both 6 
and 24  months. In the Paleolithic diet group, fat mass 
compared to baseline decreased by 19% after 6 months 
and by 14% after 24 months (Table 2). This decrease of fat 
mass was more pronounced compared to that observed 
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in the control diet group (decrease of 10% after 6 months 
and 9% after 24 months).
Glucose and insulin
Fasting glucose, fasting insulin and surrogate measures 
of insulin sensitivity are published in a separate paper 
(27). Neither group showed changes in fasting glucose 
or glucose levels after oral glucose bolus ingestion during 
the intervention (Fig. 2A, B and Table 3). Fasting insulin 
decreased between baseline and 6  months, only in the 
Paleolithic diet group (Table  3). The incremental area 
under the curve (iAUC) for insulin showed a tendency 
of declining between baseline and 24  months in both 
intervention groups (P = 0.10 for the Paleolithic diet 
group and P = 0.37 for the control diet group; Fig. 2C, D  
and Table 3).
Glucagon-like peptide-1
Fasting GLP-1 levels increased only in the control diet 
group (Table 3).
In the Paleolithic diet group, the mean iAUC of 
GLP-1 increased by 34% after 6 months and by 45% after 
Table 1 Dietary intake according to food records at baseline and during 24 months of following a Paleolithic diet (n = 26) or a 
healthy control diet based on Nordic Nutrition Recommendations (n = 22). Data are presented as mean ± S.E.M.
Paleolithic diet Control diet
Baseline 6 months 24 months Baseline 6 months 24 months
Energy intake 
 kJ/day 8221 ± 251 6790 ± 255### 6308 ± 377### 8699 ± 356 6635 ± 293### 7183 ± 268###
 kcal/day 1964 ± 60 1622 ± 61### 1507 ± 90### 2078 ± 85 1585 ± 70### 1716 ± 64###
 n 26 26 23 22 19 19
Carbohydrate intake 
 g/day 220 ± 7 119 ± 6***,### 116 ± 10**,### 231 ± 11 175 ± 7### 185 ± 12###
 E% 45.6 ± 0.6 30.0 ± 1.3***,### 31.0 ± 1.7***,### 45.0 ± 0.9 45.1 ± 1.3 43.8 ± 2.3
 n 26 26 23 22 19 19
Fat intake 
 g/day 74 ± 3 79 ± 5*** 71 ± 5 81 ± 4 55 ± 4### 66 ± 4#
 E% 33.3 ± 0.6 42.6 ± 1.3***,### 41.6 ± 1.6**,### 34.4 ± 0.8 30.1 ± 1.2# 34.2 ± 1.9
 n 26 26 23 22 19 19
Protein intake 
 g/day 83 ± 3 93 ± 3***,## 85 ± 4* 85 ± 3 75 ± 3# 72 ± 2#
 E% 17.2 ± 0.3 23.6 ± 0.6***,### 23.3 ± 0.8***,### 16.9 ± 0.6 19.6 ± 0.8## 17.3 ± 0.5
 n 26 26 23 22 19 19
Protein intake†
 g/day 100 ± 5 98 ± 4 88 ± 6 102 ± 4 94 ± 5# 88 ± 4
 E% 18.2 ± 1.0 21.4 ± 1.0## 21.9 ± 2.1# 17.9 ± 1.1 21.7 ± 2.0## 17.9 ± 1.0
 n 25 23 18 20 17 16
*P < 0.05, **P < 0.01, ***P < 0.001 for the difference between diet groups. #P < 0.05, ##P < 0.01, ###P < 0.001 for the within-group change over time vs 
baseline. †According to nitrogen excretion.
Table 2 Patient characteristic, fasting plasma β-hydroxybutyrate (BHB) and non-esterified fatty acids (NEFA) at baseline and 
during 24 months of following a Paleolithic diet (n = 26) or a healthy control diet based on Nordic Nutrition Recommendations 
(n = 23). Data are presented as mean ± s.e.m. Values within parentheses indicate number (n).
Paleolithic diet Control diet
Baseline 6 months 24 months Baseline 6 months 24 months
Age (years) 61 ± 1 61 ± 1
Weight, kg 85.5 ± 2.1 (26) 76.2 ± 2.1(25)***,### 77.3 ± 2.3 (26)*,### 84.9 ± 1.6 (23) 80.1 ± 1.8 (23)### 80.1 ± 2.0 (22)###
BMI, kg/m2 32.5 ± 0.8 (26) 28.9 ± 0.8 (25)***,### 29.3 ± 0.8 (26)*,### 32.1 ± 0.5 (23) 30.3 ± 0.6 (23)### 30.4 ± 0.7 (22)###
Fat mass, kg 39.2 ± 1.5 (26) 31.9 ± 1.5 (26)***,### 33.8 ± 1.6 (23)*,### 39.2 ± 1.1 (23) 35.3 ± 1.4 (23)### 35.7 ± 1.5 (22)###
Fasting plasma 
BHB†
3.8 ± 0.7 (25) 5.8 ± 1.3 (25)*,# 5.3 ± 0.9 (21) 3.0 ± 0.4 (22) 3.4 ± 0.8 (21) 4.1 ± 1.1 (22)
Fasting NEFA 
(mmol/L)
0.48 ± 0.04 (26) 0.42 ± 0.03 (26) 0.40 ± 0.04 (26) 0.50 ± 0.03 (23) 0.45 ± 0.03 (23) 0.45 ± 0.04 (22)
*P < 0.05, ***P < 0.001 for the difference between diet groups. #P < 0.05, ###P < 0.001 for the within-group change over time vs baseline. †Values 
represent relative concentration.
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24  months compared to baseline (Fig.  2E and Table  3). 
In the control diet group, the mean iAUC of GLP-1 did 
not increase after 6  months but increased by 59% after 
24 months compared to baseline (Fig.  2F). The increase 
of the mean iAUC for GLP-1 from 6 to 24 months was 
significant in the control diet group (P = 0.04) but not 
in the Paleolithic diet group (P = 0.75), but did not 
significantly differ between diet groups.
Association between glucagon-like peptide-1, body 
weight and food intake
During the first 6 months of control diet, the increase of 
fasting GLP-1 was associated with decreased carbohydrate 
intake (rS = −0.62, P = 0.02) and increased fat intake 
(rS = 0.54, P = 0.048). Body weight or protein intake at 
baseline or during the intervention was not associated 
with fasting GLP-1 levels.
Postprandial GLP-1 levels were inversely correlated 
with BMI at baseline (rS = −0.42, P = 0.005). Assessment 
of the whole study population revealed that the increase 
in postprandial GLP-1 between baseline and 6  months 
was associated with weight loss (Fig. 3). This correlation 
was not significant when each intervention group was 
analysed separately. Protein intake (measured by nitrogen 
excretion), fat and carbohydrate intake (reported by the 
participants) were not associated with postprandial GLP-1 
levels at baseline or during the intervention.
Glucose-dependent insulinotropic polypeptide
Fasting GIP levels did not change during the diet 
intervention.
The mean iAUC for GIP increased significantly by 
23% after 6 and 24  months compared to baseline in 
the Paleolithic diet group (Fig. 2G and Table 3). Among 
controls, the mean iAUC for GIP increased slightly (11%) 
after 24 months (Fig. 2H). The mean iAUC for GIP did not 
significantly differ between diet groups.
Association between glucose-dependent 
insulinotropic polypeptide, body weight and 
food intake
In the study population as a whole, the increase of 
iAUC GIP levels after 6 months was not associated with 
weight changes but with decreased carbohydrate intake 
(rS = −0.46, P = 0.003). This correlation was non-significant 
when each intervention group was analysed separately. 
During the first 6  months of Paleolithic diet, increased 
protein intake (E% according to nitrogen excretion) 
tended to be correlated with increased postprandial GIP 
levels (rS = 0.41, P = 0.06). Fat intake was not associated 
with postprandial GIP levels.
Changes of postprandial GIP levels during the 
intervention correlated with changes of postprandial 
GLP-1 levels (rS = 0.47, P = 0.003).
Glucagon
Fasting glucagon increased slightly at 6 months in both 
diet groups (P = 0.055 for the Paleolithic diet group and 
P = 0.052 for the control diet group) with a significant 
increase of 24% between baseline and 24 months in the 
control diet group only. The fasting glucagon/insulin 
ratio increased after 6  months compared to baseline in 
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Figure 2
Measurements of glucose (A and B), insulin (C and D), GLP-1 (E and F), GIP (G and H) and glucagon (I and J) during an oral glucose 
tolerance test after 6 and 24 months following a Paleolithic diet (A, C, E, G and I) or a healthy control diet based on the Nordic 
Nutrition Recommendations (B, D, F, H and J). Data are presented as mean ± s.e.m.
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both groups, which was sustained after 24 months in the 
control diet group (Table 3).
During the first 6  months, the mean total AUC for 
glucagon increased by 13% in the Paleolithic diet group 
and by 10% in the control diet group (Fig.  2I, J and 
Table 3). There was a tendency for postprandial glucagon 
to further increase after 24  months in the control diet 
group (P = 0.12).
Association between glucagon and body weight, 
food intake, β-hydroxybutyrate and non-esterified 
fatty acids
In the Paleolithic diet group, increasing fasting glucagon 
levels during 24 months of intervention were correlated 
with decreasing carbohydrate intake (rS = −0.50, P = 0.04) 
and increasing fat intake (pS = 0.55, P = 0.02). This 
association was not found in the control group. Fasting 
glucagon levels were not associated with body weight 
or protein intake (according to nitrogen excretion) at 
baseline or during the intervention.
The ketone body β-hydroxybutyrate increased at 
6 months in the Paleolithic diet group, with a significant 
difference versus the control diet group (Table  2). This 
increase in ketone bodies was associated with increased 
fasting glucagon (rS = 0.36, P = 0.03) and the increased 
glucagon/insulin ratio (rS = 0.46, P = 0.006) within the 
whole study population. Fasting non-esterified fatty acids 
did not change significantly during the intervention, but 
the increase in ketone bodies was associated positively 
with changes in fasting non-esterified fatty acids during 
6 months (rS = 0.32, P = 0.03) and 24 months of intervention 
(rS = 0.38, P = 0.01).
Postprandial glucagon levels were not associated 
with body weight, protein, fat or carbohydrate intake at 
baseline or during the intervention.
Table 3 Hormone profiles during an oral glucose tolerance test at baseline and over 24 months of following a Paleolithic diet 
(n = 26) or a healthy control diet based on Nordic Nutrition Recommendations (n = 23). Data are presented as mean ± s.e.m. Values 
within parentheses indicate number (n).
Paleolithic diet Control diet
Baseline 6 months 24 months Baseline 6 months 24 months
Glucose
 Total AUC (120 min × mmol/L) 902 ± 47 (25) 879 ± 43 (25) 935 ± 46 (26) 927 ± 43(22) 913 ± 46 (22) 949 ± 48 (21)
 Incremental AUC (120 min × mmol/L) 299 ± 36 (25) 296 ± 34 (25) 329 ± 32 (26) 309 ± 36 (22) 290 ± 35 (22) 322 ± 35 (21)
 Fasting concentration (mmol/L) 5.1 ± 0.2 (25) 4.9 ± 0.1 (26) 5.1 ± 0.2 (26) 5.3 ± 0.2 (23) 5.3 ± 0.2 (23) 5.2 ± 0.1 (22)
Insulin
 Total AUC (120 min × mU/L ) 7233 ± 952 (26) 6310 ± 644 (26) 6080 ± 600 (26) 9452 ± 1163 (22) 7545 ± 802 (22) 8151 ± 812 (21)
 Incremental AUC (120 min × mU/L) 6219 ± 887 (26) 5582 ± 613 (26) 5134 ± 537 (26) 8371 ± 1080 (22) 6598 ± 769 (22) 6981 ± 741 (21)
 Fasting concentration (mU/L) 8.5 ± 0.8 (26) 6.1 ± 0.4 (26)### 7.9 ± 0.7 (26) 8.8 ± 0.9 (23) 7.9 ± 0.7 (23) 9.8 ± 0.9 (22)
GLP-1
 Total AUC (120 min × pmol/L) 2424 ± 141 (24) 2769 ± 122 (25)## 2826 ± 244 (20)# 2113 ± 132 (18) 2287 ± 169 (21) 2907 ± 325 (18)##
 Incremental AUC (120 min × pmol/L) 1084 ± 99 (24) 1449 ± 111 (25)## 1572 ± 233 (20)# 933 ± 106 (18) 1036 ± 134 (21) 1488 ± 266 (18)#
 Fasting concentration (pmol/L) 11.2 ± 0.7 (24) 10.9 ± 0.6 (26) 10.8 ± 0.7 (22)* 10.1 ± 0.6 (22) 10.4 ± 0.7 (22) 11.9 ± 0.6 (20)##
GIP
 Total AUC (120 min × pmol/L) 6683 ± 559 (24) 7580 ± 664 (26)# 7593 ± 593 (18)# 6021 ± 371 (20) 5953 ± 355 (21) 6858 ± 567 (18)
 Incremental AUC (120 min × pmol/L) 4708 ± 426 (24) 5804 ± 622 (26)# 5799 ± 540 (18)## 4629 ± 349 (20) 4503 ± 334 (21) 5151 ± 534 (18)
 Fasting concentration (pmol/L) 16.5 ± 1.9 (24) 14.8 ± 1.2 (26) 16.9 ± 1.9 (21) 12.3 ± 1.2 (22) 12.1 ± 1.3 (21) 14.4 ± 1.5 (20)
Glucagon
 Total AUC (120 min × pmol/L) 496 ± 36 (23) 558 ± 42 (24)# 539 ± 34 (20) 526 ± 42 (18) 580 ± 37 (21)# 636 ± 37 (19)
 Fasting concentration (pmol/L) 5.0 ± 0.3 (24) 5.5 ± 0.5 (25) 5.7 ± 0.4 (22) 5.5 ± 0.4 (22) 5.6 ± 0.3 (22) 6.8 ± 0.4 (21)#
 Fasting glucagon/insulin ratio (pmol/mU) 0.65 ± 0.06 (23) 1.03 ± 0.10 (24)## 0.93 ± 0.11 (20) 0.70 ± 0.09 (17) 0.87 ± 0.11 (21)## 0.88 ± 0.09 (18)##
*P < 0.05 for the difference between diet groups. #P < 0.05, ##P < 0.01, ###P < 0.001 for the within-group change over time vs baseline.
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Figure 3
Association between changes observed in BMI and iAUC GLP-1 
during 6 months of Paleolithic diet (n = 22) or a healthy control 
diet based on the Nordic Nutrition Recommendations (n = 17).
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Discussion
We have found a potential explanation for the excellent diet-
induced long-term weight reduction in the present cohort 
of obese postmenopausal women (18). The intervention 
caused an increase in postprandial GLP-1 levels that was 
associated with weight loss but not with macronutrient 
composition of the diet. Interestingly, postprandial GLP-1 
levels further increased during up to two years of weight 
maintenance. Moreover, the Paleolithic diet intervention 
led to an increased GIP response to glucose that was not 
associated to changes in body weight but to changes in 
macronutrient composition of the diet. We also detected 
a concomitant slight increase in fasting glucagon levels, 
which was reflected in less suppressed postprandial AUCs 
and was not associated with weight loss.
Weight loss during the first 6  months of our study 
caused an increase in postprandial GLP-1 levels, which was 
significant only in the Paleolithic diet group. Interestingly, 
postprandial GLP-1 levels increased even further between 
6 and 24 months when body weight remained stable (now 
significant also in the control group). Two earlier studies 
in healthy obese individuals have shown comparable 
results: increasing postprandial GLP-1 levels after weight 
loss and a further increase after weight maintenance (13, 
14). However, other weight loss studies in healthy obese 
individuals showed unchanged or decreased postprandial 
GLP-1 levels (28, 29, 30).
There are several possible explanations for 
these divergent results. The method used for GLP-1 
measurement may be a major contributing factor. Two 
studies measured only active GLP-1 (28, 29). Active GLP-1 
is rapidly degraded to the inactive form (t1/2 ≈ 1.5 min), 
such that only 10% of secreted GLP-1 ever reaches the 
circulation in its active form (31). Thus, it is very difficult 
to detect changes in GLP-1 secretion using this method. 
Here we measured total GLP-1, including both the active 
form and the primary GLP-1 metabolite, which provides 
a better estimate of GLP-1 secretion (23). It is also notable 
that all three weight loss studies that found decreasing 
or unchanged postprandial GLP-1 were short-term studies 
of very low-calorie diets (28, 29, 30). An acute negative 
energy balance on the examination day or in the days 
before measurement may cause increased plasma levels 
of non-esterified fatty acids, which could decrease GLP-1 
secretion (32). In this scenario, a shorter study period 
might induce smaller changes that would likely become 
apparent over time given that the AUC for GLP-1 increases 
further during a period of weight loss maintenance. 
Although it is presently unclear how postprandial GLP-1 
levels change during periods of negative energy balance 
and concomitant rapid weight loss, the available evidence 
suggests that postprandial GLP-1 increases after weight 
loss followed by a longer period of neutral energy balance 
and weight maintenance. It is possible that GLP-1 may 
be key to preventing weight regain via efficient diet 
interventions, as the postprandial increases after weight 
loss may contribute to increased satiety.
The Paleolithic diet group also exhibited increased 
postprandial GIP levels, but this increase was not associated 
with weight loss. Three previous studies also report 
increased postprandial GIP levels after short-term weight 
loss with a very low-calorie diet (14, 28, 30). However, 
increased, decreased and unchanged postprandial GIP 
levels are reported after weight maintenance (13, 14, 
28). Notably, we did not find any significant changes of 
postprandial GIP levels in our control diet group. The 
more pronounced weight loss in the Paleolithic diet group 
compared to the control diet group may thus contribute 
to this result. However, factors other than weight loss 
may be responsible for the increase in postprandial GIP 
levels in the Paleolithic diet group. Studies in rodents 
demonstrate that dietary fat consumption chronically 
stimulates GIP production and secretion and even induces 
hyperplasia of GIP-producing K cells (33). In our study, 
individuals in the Paleolithic diet group had higher fat 
consumption and lower carbohydrate intake compared 
to those in the control diet group, and we found that 
decreased carbohydrate intake was associated with 
increased postprandial GIP levels. These results are in line 
with the findings of Sloth and colleagues, demonstrating 
lower postprandial GIP levels associated with 6 months 
of weight maintenance with a low-fat diet compared to a 
control diet with higher fat content (34). Therefore, the 
increased postprandial GIP levels in the Paleolithic diet 
group of our study could either be due to altered diet 
composition or to a more pronounced weight loss.
As discussed earlier, it is suggested that glucagon may 
also decrease the appetite – even more so when it acts 
together with GLP-1 (35, 36), but the influence of weight 
loss on glucagon secretion in healthy individuals without 
diabetes has not been extensively studied. Iepsen and 
colleagues found no changes in fasting or postprandial 
glucagon levels in healthy obese individuals during 
8  weeks on a very low-calorie diet and 1  year of body 
weight maintenance (14). In our study, both diet groups 
exhibited increased postprandial glucagon, which was not 
associated with weight loss or macronutrient composition 
of the diet. Examination of the postprandial glucagon 
responses (Fig.  2I and J) revealed a tendency towards 
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increased fasting glucagon levels after 6 and 24 months 
of intervention, moving the whole graph slightly upward. 
However, glucose-induced suppression was unaltered.
Glucagon maintains stable blood glucose levels 
during fasting by promoting hepatic glucose production, 
mostly through glycogenolysis. Both diets in our study 
induced weight loss via reduced calorie intake (despite 
ad libitum intake according to study design), which 
may in itself increase fasting glucagon secretion. Some 
participants probably had a very low-calorie intake the 
days before measurement causing a catabolic state during 
examination, as supported by increased levels of the ketone 
body β-hydroxybutyrate in concert with higher fasting 
non-esterified fatty acids. Therefore, the less suppressed 
postprandial glucagon levels during our intervention can 
be interpreted as a physiological reaction to a catabolic 
state. Indeed, we identified a significant association 
between increased ketone bodies and increased fasting 
glucagon levels. The altered protein and fat intake in both 
diet groups may influence both ketogenesis and amino 
acid metabolism.
The participants in this study were metabolically 
healthy: glucose and insulin, both fasting and 
postprandially, were within the normal range. This 
explains why glucose and insulin showed only minor 
changes after the intervention despite the significant 
weight loss. It is important to have this healthy study 
population in mind when interpreting the results of GLP-
1, GIP and glucagon. Individuals with impaired glucose 
tolerance or diabetes would have had higher glucagon 
levels and lower GLP-1 levels at study start which 
would have influenced the weight loss effect on these 
hormones (10, 20).
The present study has several limitations. First, it is 
difficult to disentangle the effects of weight loss and diet 
composition, respectively, on hormonal changes. Notably, 
the Paleolithic diet causes a more pronounced weight loss 
compared to the control diet. The correlation analyses 
can therefore not infer causality. Second, not all enrolled 
women completed the study. Our analysis includes only 
the individuals who did not leave the study protocol. The 
women who remained in the study probably achieved 
greater weight loss than those who left the study. This 
fact introduces selection bias but gives us the possibility 
to study the effect of more pronounced weight loss. 
We cannot exclude the possibility that hormone levels 
differed in individuals who discontinued the study. Third, 
we examined incretin and glucagon levels using an oral 
glucose tolerance test, but a mixed meal test would have 
provided a more physiological examination. Fourth, our 
study protocol only included examination of incretin 
secretion. Incretin sensitivity may also be important for 
weight loss and weight maintenance, but was not assessed 
in this study. Fifth, incretin hormone and glucagon 
levels were analysed in batch after completion of the 
study. Because of the long study duration, storage time 
differed between baseline and 2-year samples which may 
influence hormone levels. Incretin and glucagon levels 
were analysed 4 years after study completion. Glucagon 
levels are mostly reduced during the first month of storage 
and much less during the following months (37). GLP-1 
levels are more or less stable during 1 year of storage (37). 
Due to the long storage time after completion of the 
study, the study duration of 2 years is less important for 
the analysis results.
In summary, our study suggests that weight loss 
increases postprandial GLP-1 levels, which promote 
satiety and help to maintain body weight after weight 
loss. During time periods where metabolism is in a 
slightly catabolic state, less suppressed glucagon levels 
may enhance this effect of GLP-1.
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